ArticleIndian journal of thoracic and cardiovascular surgery2026
Use of LVAD HeartMate 3 and Impella RP in the management of advanced heart failure in an elderly patient: a case report.
Article in Indian journal of thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a leading cause of morbidity and mortality. Mechanical circulatory support (MCS), such as the HeartMate 3 left ventricular assist device (LVAD), is a therapeutic option for patients who are ineligible for heart transplantation. Right heart failure (RHF), depending on the clinical criteria applied for its diagnosis, occurs in 10-40% of patients following LVAD implantation and significantly worsens prognosis. This report presents a 69-year-old male with chronic ischemic HF, prior cardiac resynchronization therapy with defibrillator (CRT-D) implantation, and coronary intervention with drug-eluting stents. Due to progressive mitral regurgitation (MR) and elevated HF biomarkers, MitraClip implantation was performed with initial clinical improvement. Subsequently, left ventricular function deteriorated despite optimized pharmacotherapy, leading to HeartMate 3 LVAD implantation. The postoperative course was complicated by recurrent cardiac tamponade requiring surgical management. Progressive RHF necessitated temporary support with an Impella RP device. Further complications included recurrent infections, sepsis, respiratory failure, and acute kidney injury requiring renal replacement therapy. Despite comprehensive treatment, progressive multiorgan failure and severe cachexia developed. Given the patient's status as a destination therapy, care was transitioned to home-based palliative management. This case illustrates the complexity of managing end-stage HF with LVAD support, highlighting the frequent complications such as RHF and infections, and the importance of recognizing when to prioritize comfort in advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.